OUP (Osage University Partners)
Venture capitalBala Cynwyd · Pre-Seed–Late Stage · 23 people tracked
Also known as Osage University Partners · OUP MANAGEMENT CO., LLC
Investment thesis
OUP invests in science-driven startups commercializing transformational, disruptive deep technology emerging from or inspired by breakthrough university research. With over 15 years of focused experience, the firm positions itself as a preferred partner for entrepreneurs, scientists, and students navigating the difficult path of turning laboratory discoveries into market-ready products. Its team of former scientists, strategy consultants, and operators supports portfolio companies through domain expertise, tech transfer navigation, product development guidance, and connections to Fortune 500 leaders, strategic partners, and co-investors. OUP acts as a long-term partner, reserving meaningful capital for follow-on rounds and working alongside founders as they evolve early research into commercial businesses.
Source: firm website, verified Aug 11, 2026.
Team · 23 people
from the firm's website & public directories
What they invest in
from 61 of 121 portfolio companiesBiotech ×35AI & Machine Learning ×17Healthtech ×17Medical Devices ×13Deep Tech ×11Enterprise Software ×7Hardware ×6Advanced Manufacturing ×5
HQs:United States×62Israel×2
Investments · 121 tracked
founders shown can be your intro pathBy year:2025 · 22024 · 12022 · 12021 · 12020 · 22019 · 12018 · 22017 · 12016 · 12015 · 113 dated
Ambiq develops ultra-low-power semiconductor solutions and edge AI platforms for IoT and healthcare applications.
AI & Machine LearningIoTSemiconductorsAustin, US
Scott Hanson(Executive Officer, Director)Fumihide Esaka(CEO)Scott Goodwin(Executive Officer)Joseph A. Tautges(Director)Paul Rolls(Executive Officer)Sean Chen(Executive Officer, Director)
Beam Therapeutics develops gene-editing medicines, particularly base editors and precision genome editing technologies, to create lifelong cures for patients with serious genetic diseases.
BiotechDeep TechMedical DevicesCambridge, US
David R. Liu(Founder and Inventor)J. Keith Joung(Founder and Inventor)Feng Zhang(Founder and Inventor)CAROLE HO(Director)John Evans(Executive Officer, Director)MARK FISHMAN(Director)
Waltham, US
Kevin O'Brien(Executive Officer)Joel Cutler(Director)Anil Chitkara(Executive Officer)Patrick Ennis(Director)Michael Ellenbogen(Executive Officer, Director)John Sanders(Director)
Guardant Health develops blood-based testing (liquid biopsy) for cancer detection and monitoring across all stages of the disease.
BiotechDigital HealthHealthtechMedical DevicesRedwood City, US
AmirAli Talasaz(Executive Officer, Director)Warren Hogarth(Director)Michael Wiley(Executive Officer)Helmy Eltoukhy(Executive Officer, Director)
BoardSamir Kaul(Director)
Kura Oncology is a company in the oncology/medtech sector that provides grant support for independent medical education programs designed to enhance healthcare professionals' ability to diagnose and treat patients in Kura Oncology's therapeutic areas of interest.
BiotechDigital HealthMedical DevicesLa Jolla, US
HEIDI HENSON(Executive Officer)TROY WILSON(Executive Officer, Director)ANNETTE NORTH(Executive Officer)PINGDA REN(Executive Officer)YI LIU(Executive Officer)ANTONIO GUALBERTO(Executive Officer)
BiotechCranbury, US
David Mack(Executive Officer, Director)Peter Thompson(Director)Steve Winick(Director)Arnold Oronsky(Director)Arnold Levine(Director)
Precision BioSciences is a clinical-stage biotechnology company developing genome-editing therapies based on its ARCUS platform.
BiotechDeep TechHealthtechDurham, US
JEFF SMITH(Executive Officer)DEREK JANTZ(Executive Officer, Director)MATTHEW KANE(Executive Officer, Director)TODD MELBY(Executive Officer)BEN AUSPITZ(Director)Jeff Smith(Co-founder)
Prime Medicine develops one-time genetic therapies using Prime Editing, a gene editing technology developed in David R.
BiotechDeep TechHealthtechMedical Devices
Andrew Anzalone(Co-founder and Head of Platform)David Liu(Co-founder)Allan Reine(Chief Executive Officer)Mohammed Asmal(Chief Medical Officer)Ann Lee(Chief Technical Officer)Svetlana Makhni(Chief Financial Officer)
HealthtechSalt Lake City, US
Mansoor Mirza(Director)Marcus Wilson(Director)Ryan M. Trimble(Director)Dennis B. Farrar(Director)Douglas Fisher(Executive Officer)Kim Kamdar(Director)
BiotechCambridge, US
Patrick Vink(Director)Milind Deshpande(Director)Jean-Francois Formela(Director)Casper Breum(Director)Ankit Mahadevia(Executive Officer, Director)Stephen Garbacz(Executive Officer)
Veradermics is a dermatologist-founded, late clinical-stage biopharmaceutical company developing therapeutics for pattern hair loss in men and women.
BiotechHealthtechWest Hartford, US
John W. Childs(Director)Reid Waldman(Executive Officer, Director)Jane Grant-Kels(Director)Vladimir Coric(Director)Timothy Durso(Executive Officer, Director)
Aerie Pharmaceuticals develops ophthalmic pharmaceutical products including Rocklatan and Rhopressa for glaucoma and ocular hypertension, and AR-15512 for dry eye disease.
BiotechHealthtechMedical Devices
Boston, US
Ann Arbor, US
Valeria Bertacco(Director)Todd Austin(Chief Executive Officer)Lip-Bu Tan(Director)
Seattle, US
Kenneth F. Daniel(Executive Officer, Director)Timothy Porter(Director)Diego M. Oppenheimer(Executive Officer, Director)
BoardAnna Patterson(Director)
BiotechNew Haven, US
Ranjit Bindra(Director)Barbara Fox(Executive Officer, Director)Nicholas J Galli(Executive Officer, Director)Kevin L. Rakin(Executive Officer, Director)Stanley Choy(Executive Officer)
BoardColleen Cuffaro(Director)
Antiva Biosciences develops a topical therapeutic for women with high-risk HPV infection and pre-cancerous cervical lesions, utilizing antiviral prodrug chemistry.
BiotechFemTechHealthtechMedical DevicesRedwood City, US
Gail Maderis(Director)Kristine Ball(Executive Officer, Director)Elaine Chien(Executive Officer)Sarah Walter(Executive Officer)Raju Gadiraju(Executive Officer)Steven James(Director)
BiotechEvanston, US
Joseph R. Moskal(Chief Scientific Officer)Torsten M. Madsen(Chief Marketing Officer)Liam Ratcliffe(Director)Ashish Khanna(Secretary & Chief Business Officer)Terry P. Gould(Director)Wilbur H. Gantz III(Director)
Arrakis Therapeutics discovers and develops RNA-targeted small-molecule drugs, a new drug modality that acts directly on RNA to treat diseases previously inaccessible to genetic medicine.
AI & Machine LearningBiotechDeep TechCambridge, US
Michael Gilman(Executive Officer, Director)Carolyn Green(Director)Alan E. Walts(Director)David Neafus(Executive Officer)Russell C. Petter(Executive Officer)Mark DeLong(CEO)
Programmable CAR-T therapies using genetic circuits and CRISPR for cancer treatment
AssetWatch provides cloud-based asset monitoring software and sensor technology to help manufacturing and industrial facilities prevent unplanned equipment downtime.
Advanced ManufacturingEnterprise SoftwareIoTSaaSWesterville, US
Brian Graham(Executive Officer, Director)inWilliam Zell(Executive Officer, Director)William Ruff(Executive Officer)Robert Lee(Director)Tad Dritz(VP of Development)John D'Orazio(Director)
Biohaven is a biopharmaceutical company focused on discovering and developing treatments in immunology, obesity, neuroscience, and oncology, including approved migraine medications.
BiotechHealthtechMedical Devices
BiotechSouth San Francisco, US
Cameron Wheeler(Director)Elaine Jones(Director)Wendye Robbins(Executive Officer, Director)William Slattery(Director)James Scopa(Director)
BoardLuke Evnin(Director)
New York, US
Joseph Ferrara(Director)Lawrence Lenihan(Director)William J. O'Farrell(Executive Officer, Director)Michael Black(Director)
Brimstone develops co-production processes to manufacture cement, steel, aluminum, and other critical minerals from a single feedstock in an integrated facility.
Advanced ManufacturingCircular EconomyCleantechConstruction TechNew MaterialsOakland, US
Cody Finke(CEO)Hugo Leandri
BiotechLafayette, US
Fred Cohen(Executive Officer, Director, Promoter)Arie Belldegrun(Director)Peter Emtage(Executive Officer)Andrew Allen(Director)Greg Giotta(Executive Officer)Brian Atwood(Executive Officer, Director, Promoter)
Clarifai developed AI inference technology and compute orchestration software for running and optimizing machine learning models at scale.
AI & Machine LearningCloud ComputingData & InfrastructureNew York, US
Matthew Zeiler(Executive Officer, Director)
BoardAlbert Wenger(Director)
Cyteir is a clinical-stage oncology company developing CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters.
BiotechHealthtechCambridge, US
Kevin Mills(Executive Officer, Director)Barry Mills(Director)Ronald Goldstein(Executive Officer)Donald Corcoran(Executive Officer, Director)Timothy Romberger(Director)Markus Renschler(Director)
DELFI Diagnostics develops FirstLook Lung, a blood-based laboratory test for lung cancer screening that identifies genome-wide alterations in individuals eligible for screening.
AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesBaltimore, US
Peter Bach(Executive Officer)Elizabeth Homans(Director)Justin Kao(Director)Jennifer Buechel(Executive Officer)Victor Velculescu(Executive Officer, Director, Promoter)Douglas Schenkel(Executive Officer)
Dracen Pharmaceuticals is a private drug developer working at the intersection of cancer metabolism and immuno-oncology, developing glutamine antagonists that inhibit tumor glutamine metabolism and remodel the tumor microenvironment.
BiotechHealthtechBaltimore, US
Drew Pardoll, M.D., Ph.D.(Director)Thomas M. Estok(Chief Executive Officer, President and Treasurer)Asher Rubin(Secretary)Robert Jackson(Director)Robert Wild(Co-founder & Chief Scientific Officer)
BoardJonathan Leff(Director)
BiotechSouth San Francisco, US
R. Sanders Williams(Director)Perry Karsen(Director)Asish Xavier(Director)Judith Li(Director)Markus Goebel(Director)Peter Moldt(Director)
eFFECTOR Therapeutics was a clinical-stage biopharmaceutical company.
BiotechSolana Beach, US
Stephen F. Worland, Ph.D.(Executive Officer, Director)Alana McNulty(Executive Officer)Simeon George(Director)Ken Haas(Director)Laurence Lasky(Director)Markus Goebel(Director)
BiotechBrookline, US
Luhan Yang(President, Secretary and Treasurer)Geoff MacKay(Chief Executive Officer)
BoardGeorge M. Church(Director)
Elementary builds data observability tools that monitor data quality and reliability for modern data teams.
AI & Machine LearningData & InfrastructureDeveloper ToolsEnterprise SoftwareTel Aviv-Yafo, IL
Maayan Salom(Founder)inOr Avidov(Founder)in
Elementary Robotics builds a factory AI stack for automated visual quality inspection, combining machine vision hardware (cameras, lighting, edge controllers), self-training defect-detection AI (VisionStream), and a cloud platform (QualityOS) for traceability and analytics.
Advanced ManufacturingAI & Machine LearningRobotics
BiotechSan Diego, US
JeenJoo Kang(Director)Robert Tjian(Director)Alain Baron(Executive Officer, Director)Marcus Boehm(Executive Officer)Andrew Schwab(Director)
San Jose, US
Benton Calhoun(Executive Officer, Director)David Wentzloff(Executive Officer, Director)Brendan R Richardson(Executive Officer, Director)Jack Busch(Director)
BoardGeorge Kastendike(Director)Greg Papadopoulos(Director)
Exits · 15
IPOs and acquisitions across the tracked portfolioAmbiqNYSE: AMBQBeam TherapeuticsNASDAQ: BEAMEvolv TechnologiesNASDAQ: EVLVGuardant HealthNASDAQ: GHIonQNYSE: IONQKura OncologyNASDAQ: KURAPMV PharmaceuticalsNASDAQ: PMVPPrecision BioSciencesNASDAQ: DTILPrime MedicineNASDAQ: PRMEQ32 BioNASDAQ: QTTBSera PrognosticsNASDAQ: SERASpero TherapeuticsNASDAQ: SPROVeradermicsNYSE: MANEVor BiopharmaNASDAQ: VORSynthorxacq. by Sanofi
Portfolio news
latest coverage across their companiesVeradermics · tipranks.com · Aug 3, 2026
Arrakis Therapeutics · runtimewire.com · Aug 2, 2026
Overland Ai · thedefensepost.com · Jul 17, 2026
Ambiq · simplywall.st · Jul 17, 2026
Guardant Health · investing.com · Jul 16, 2026
Elementary · hanfordsentinel.com · Jul 14, 2026
Kura Oncology · manilatimes.net · Jul 14, 2026
Delfi Diagnostics · geekwire.com · Jul 13, 2026
Frequently asked questions
- What stage does OUP (Osage University Partners) invest at?
- OUP (Osage University Partners) invests at the Pre-Seed, Seed, Series A, Series B, Series C, Growth, Late Stage stages.
- What is OUP (Osage University Partners)'s typical check size?
- OUP (Osage University Partners) typically writes checks of $1M – $20M.
- What sectors does OUP (Osage University Partners) focus on?
- OUP (Osage University Partners) focuses on AI & Machine Learning, Biotech, Cleantech, Climate Tech, Cloud Computing, Cybersecurity, Deep Tech, Digital Health, Energy, Enterprise Software, Hardware, Healthtech, Medical Devices, New Materials, Quantum Computing, SaaS, Sector Agnostic, Semiconductors.
- Where is OUP (Osage University Partners) located?
- OUP (Osage University Partners) is headquartered in Bala Cynwyd, US.
- Does OUP (Osage University Partners) lead rounds?
- Yes, OUP (Osage University Partners) leads investment rounds.
Media · Podcasts & interviews
featuring the teamUniversity Spinouts and Deep Tech Investing | Marc Singer | Osage University Partners (OUP)
Deep Tech Leaders · Marc Singer
Ventures #15 w/ Matt Cohen - Managing Partner @ Osage University Partners (OUP) | BIOS
BIOS · Matt Cohen
Founder's Equity: Formation, Dilution, Industry Averages - Manny Stockman, Osage University Partners
UCLA TDG · Manny Stockman
Marc Singer, John Lee (Osage University Partners)
Marc Singer · vimeo.com
SBIR/STTR Reauthorization: Tips and Tricks for Navigating New Funding Opportunities
Osage University Partners
Exploring Venture Debt: A Strategic Option for Startup Growth
Osage University Partners
Images
Co-investors · 47
Canaan is an early-stage venture capital firm backing founders with transformative ideas across technology and healthcare.
Lux Capital's portfolio page showcasing select companies across science and technology sectors including AI infrastructure, aerospace, biotech, and productivity software.
5AM Ventures is a life science venture capital firm founded in 2002 that invests primarily in private therapeutic companies, with a focus on biopharmaceuticals, drug delivery technologies, and life science instruments.
Khosla Ventures is a venture capital firm known for backing bold, contrarian bets in world-class teams that can reshape entire industries.
US Venture Partners (USVP) is an early-stage venture capital firm investing in information technology and healthcare companies, with four decades of investing experience.
OrbiMed is a global healthcare-focused investment firm providing financing and operational support to companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.
MPM BioImpact combines 30+ years of biotech venture capital expertise with impact investing and public market experience, managing early-stage venture funds, private/public impact funds, and a public equities fund focused on transforming patient outcomes.
Nextech Invest is a Zurich-based investment firm focused on emerging biotechnology companies, backing transformative cancer medicines and precision medicine advances worldwide.
Hatteras Venture Partners is a venture capital firm focused on early-stage life sciences and healthcare companies, backing therapeutics, diagnostics, and businesses aiming to transform healthcare delivery and innovation.
Agent Capital is a healthcare venture capital firm that invests in novel, differentiated therapeutics and treatments addressing unmet patient needs across all stages of development.
Braemar Energy Ventures is a venture capital firm that invests in energy technology and cleantech companies, including EV charging, carbon capture, demand response, and renewable fuels.
New Enterprise Associates (NEA) is a venture capital firm that invests in and provides long-term support to founders building new companies.
▶35 more co-investors
Madrona Venture GroupSierra VenturesG2 Venture PartnersMassMutual VenturesEngineering CapitalSR One Capital ManagementDeerfield Management CompanyThe Column GroupAPERTURE Venture PartnersGeneral CatalystBessemer Venture PartnersPlug and Play VenturesCompany CapitalJavelin Venture PartnersAmerican Express Ventures (Amex)Breakthrough Energy VenturesJAZZ Venture PartnersEQT Life SciencesGutbrain VenturesVersant VenturesJohnson & Johnson Innovation – JJDCDeep Fork CapitalDomain AssociatesCalibrate VenturesVenture Guides Management, L.P.Pivotal Life SciencesNewfund CapitalAmara VCOmega FundsRiverVest Venture PartnersMedical Excellence CapitalChrysalixAberdare VenturesBrightCap Investment Advisor ADSignet Healthcare Partners
Firms observed investing alongside OUP (Osage University Partners), from public investor directories. Shared companies are the overlap with OUP (Osage University Partners)'s recorded portfolio.
Similar investors
DCVC (Data Collective) is a venture capital firm that backs founders building companies which apply technology to major challenges across areas such as energy, biotech, agriculture, and machine learning.
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests from seed to growth stages across artificial intelligence, health, and sustainability-focused technologies.
Everywhere Ventures is an early-stage venture firm that backs founders globally, supported by a community of founders and operators as LPs.
Lauder Partners, LLC is a technology-focused investment entity that invests both directly in companies and in funds (venture and other), primarily deploying the capital of Gary Lauder and his family.
B Capital Group is a global venture capital firm that backs founders from early to late stage, with dedicated stage-based funds and a portfolio spanning technology, healthcare, and energy and resilience sectors.